CanVECTOR Network

The Canadian Venous Thromboembolism Research Network is a pan-Canadian, patient-oriented research network dedicated to VTE.

[CanVECTOR Network @canvector]

Join us for the final 2025–26 National #Thrombosis seminar: "Precision in DOAC reversal — a trainee-led UK network."

June 8, 12:00 ET | Featuring Dr Richard Buka !

Register to attend: https://t.co/4FyU19hC0U

#Anticoagulation #VTE #Research

[INVENT-VTE @INVENT_VTE]

The debate over DOAC selection just got clearer. 🔍

The #COBRRA trial provides a definitive head-to-head look at bleeding risks in #VTE. Tomorrow, we explore the findings!

Join the deep dive with @LanaCastellucci

Register to attend🔗 https://t.co/HdiDXD52Z8

#Research

[ISTH @isth]

Susan Kahn is a leading voice in venous thrombosis & its long-term complications. Her work has helped shape patient care and clinical practice globally. Now honored with the 2026 ISTH Esteemed Career Award, she reflects on her career: https://t.co/hkveUMn7wd

[NEJM @NEJM]

In an international, randomized trial involving patients with acute venous thromboembolism, the risk of clinically relevant bleeding was significantly lower with apixaban than with rivaroxaban during the 3-month treatment period. Full COBRRA trial results and Research Summary: https://t.co/tvPYrBCWj8

[IRSC @IRSC_CIHR]

Dans le cadre d’une étude menée par la Dre Lana Castellucci, deux types d’anticoagulants souvent utilisés pour traiter la thromboembolie veineuse ont été comparés. L’un de ces médicaments a pu diminuer de plus de 50 % les cas d’hémorragie.

https://t.co/sHBPvlApo6

[CIHR @CIHR_IRSC]

A study led by Dr. Lana Castellucci compared two types of anticoagulants commonly used to treat venous thromboembolism and showed that one of the medications reduced bleeding by more than 50%.

Learn more: https://t.co/IGN4Rev8Hr
#BloodClotAwarenessMonth

[CTV Ottawa @ctvottawa]

Groundbreaking research at The Ottawa Hospital https://t.co/LYdc1ZUhZt

[Nicola Potere @NicolaPotereMD]

🐍 COBRRA trial finds ↓ clinically relevant bleeding with apixaban vs. rivaroxaban during the first 3 months of treatment for acute VTE (RR 0.46, 95% CI 0.33–0.65)🩸

@uOttawaMed @OttawaHospital @CIHR_IRSC @INVENT_VTE

[CTV Ottawa @ctvottawa]

Ottawa Hospital research finds ‘clear winner’ for safer blood clot treatment https://t.co/RDTNvp7Mwt

[NEJM @NEJM]

In an international, randomized trial involving patients with acute venous thromboembolism, the risk of clinically relevant bleeding was significantly lower with apixaban than with rivaroxaban during the 3-month treatment period.

Full COBRRA trial results: https://t.co/tvPYrBCWj8

[Marc Carrier @MarcCarrier1]

Excited to share this fantastic new tool from @ASH_hematology

https://t.co/px2XkLlTBD

TrialMap is the perfect resource for early-career clinician investigators. Guiding you from trial concept 💡 to practice-changing results 📄.

A must-bookmark if launching a clinical trial!

[Thrombosis Canada @ThrombosisCan]

In ARTESiA:
Stroke ↓ 37%
Major bleeding ↑
Fatal & intracranial bleeding: similar
Understanding severity — not just frequency — changes the conversation.
New episode of CLOT Conversations: https://t.co/ikbqjDKbjp
#Anticoagulation #AFib #Thrombosis @DebSiegal

[INVENT-VTE @INVENT_VTE]

Can we safely rule out #DVT using age-adjusted D-dimer cutoffs? 🩺

Join our 1st 2026 Global Thrombosis Seminar! Dr. Grégoire Le Gal discusses the #ADJUST-DVT study (recently in @JAMA_current).

🗓️ Feb 25 🕘 14:00 UTC

🔗Register: https://t.co/fQr73UQQba

#VTE #MedEd #Research

[Faizan Khan, PhD @FaizanK91]

‼️So exciting to have one of my #BantingCanada postdoc projects, published last year in the #EuropeanHeartJournal, recognized among the Top 10 Research Papers of 2025 in the field of #CardioOncology 🙏🏼🎉

https://t.co/YIsj0Hg7S9

[ISTH @isth]

📣 NEWS: The ISTH announces five global recipients of 2026 Esteemed Career Awards! This award honors leaders in thrombosis and hemostasis whose life-long achievements have shaped the field through scientific excellence.

Learn more: https://t.co/86YvNQvs34

[CanVECTOR Network @canvector]

Join us for our upcoming National #Thrombosis Seminar on "Periprocedural Anticoagulation Management for Central Line Insertion in Persons with Cancer."

Featuring: Dr. Jameel Abdulrehman - University of Toronto

📅 Feb 11 at 12:00 p.m. ET.

Register: https://t.co/7g0CbLIIrP

[CanVECTOR Network @canvector]

📢 Funding & Training Opportunities

Applications are OPEN for the Fall 2025 #CanVECTOR competitions:

✅ Pilot Study Funding ✅ Research Start-Up Awards ✅ Fellowships

PLUS: The Dr. Jack Hirsh Fellowship via @HamHealthSci & @McMasterU!

🔗 https://t.co/6ogszEjo4O

[CanVECTOR Network @canvector]

Join us today at 12pm ET for our next National Thrombosis Seminar on "Biomarkers & Genetics for the Prediction of #VTE & Clinically Relevant Bleeding in Cancer Patients" -

Featuring: Danielle Roy, PhD

Register: https://t.co/SZkCPqoEQQ

#Thrombosis #Research

[Marc Carrier @MarcCarrier1]

🩺🧠 I will be chairing this Morning Report–style thrombosis cases, discussed live by an expert panel seeing the cases for the first time.

🎯 Perfect for thrombosis nerds

💻 Free & open to all. Register now! 👇

Hosted by @ThrombosisCan
🩸 #Thrombosis #MedEd

[Thrombosis Canada @ThrombosisCan]

New CPD Webinar: Clinical Challenges in Thrombosis II

Live, unscripted cases. Real-time expert discussion.

March 3 | 7:00 PM ET
Register: https://t.co/M0O7voRZJh